LHW090
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $147,902 | 3 | 0 |
| 2017 | $156,716 | 7 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $304,618 | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A TWO PART RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO CONTROLLED STUDY TO EVALUATE THE RENAL SAFETY TOLERABILITY AND PHARMACOKINETICS OF LHW090 IN PATIENTS WITH MODERATELY IMPAIRED RENAL FUNCTION ON ANGIOTENSIN RECEPTOR BLOCKERS | Novartis Pharmaceuticals Corporation | $219,897 | 0 |
| A RANDOMIZED SPONSOR OPEN SITE AND SUBJECT DOUBLE BLIND PARALLEL GROUP PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LHW090 AFTER 4 WEEKS TREATMENT IN PATIENTS WITH RESISTANT HYPERTENSION | Novartis Pharmaceuticals Corporation | $84,721 | 0 |
Top Doctors Receiving Payments for LHW090
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Jacksonville, FL | $304,618 | 10 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $304,618
Product Information
- Type Drug
- Total Payments $304,618
- Total Doctors 0
- Transactions 10
About LHW090
LHW090 is a drug associated with $304,618 in payments to 0 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $147,902 was paid across 3 transactions to 0 doctors.
The most common payment nature for LHW090 is "Unspecified" ($304,618, 100.0% of total).
LHW090 is associated with 2 research studies, including "A TWO PART RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO CONTROLLED STUDY TO EVALUATE THE RENAL SAFETY TOLERABILITY AND PHARMACOKINETICS OF LHW090 IN PATIENTS WITH MODERATELY IMPAIRED RENAL FUNCTION ON ANGIOTENSIN RECEPTOR BLOCKERS" ($219,897).